UBS Group’s Oaktree Acquisition Corp III Life Sciences Warrant OACCW Stock Holding History

UBS Group’s Portfolio OACCW Stock Details OACCW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$138	Hold	262	–	–	﹤0.01%	10086
2025 Q4	$183	Sell	262 -1,046	-80%	-$873	﹤0.01%	10123
2025 Q3	$981	Sell	1,308 -24,144	-95%	-$19.5K	﹤0.01%	9469
2025 Q2	$22.3K	Sell	25,452 -5,578	-18%	-$4.3K	﹤0.01%	8361
2025 Q1	$23.3K	Buy	+31,030	New	+$23.6K	﹤0.01%	8123

Other funds holding OACCW

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

DAM

Decagon Asset Management London, United Kingdom $386M AUM 45.42% 1-Year Est. Return

BGIM

Boussard & Gavaudan Investment Management London, United Kingdom $1.06B AUM 4.58% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

UBS Group's OACCW Position: Q1 2026 in Review

UBS Group held its Oaktree Acquisition Corp III Life Sciences Warrant (OACCW) position steady in Q1 2026 at 262 shares worth $138. The position accounts for ﹤0.01% of the portfolio, ranked #10086.

UBS Group first reported a position in OACCW in Q1 2025 and has held it in 5 quarters since. The position peaked at $23.3K in Q1 2025. 26 funds tracked by Wall St. Rank hold OACCW as of Q1 2026.

UBS Group held 262 shares of Oaktree Acquisition Corp III Life Sciences Warrant worth $138 as of Q1 2026.
UBS Group left its Oaktree Acquisition Corp III Life Sciences Warrant share count unchanged in Q1 2026.
Oaktree Acquisition Corp III Life Sciences Warrant made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10086 holding.
UBS Group first reported a position in Oaktree Acquisition Corp III Life Sciences Warrant in Q1 2025 and has held it in 5 quarters since.
UBS Group's Oaktree Acquisition Corp III Life Sciences Warrant position peaked at $23.3K in Q1 2025.
26 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences Warrant as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.